| BackgroundHyperlipidemia refers to a abnormal systemic lipid metabolism with high serum cholesterol, high triglyceride and (or) high LDL or low serum high-density lipoprotein. With the development of society and economy, more and more people are suffering from hyperlipidemia. The pathological basis of atherosclerosis was caused by this disease, when atherosclerosis, stenosis developed to a certain extent, there will appeared coronary heart disease, stroke and other serious cardiovascular disease, which has higher mortality and morbidity. Therefore, control blood lipids is great significance of prevent cardiovascular disease.With the development of Modern medical research in hyperlipidemia, more and more research and development of lipid-lowering drugs are used in clinical disease, and achieved good results, but there are still some patients who are not sensitive to the lipid-lowering drugs, and clinical adverse events have occurred, Chinese medicine has made great progress in terms of the treatment of this disease, and has certain advantages, but there are still shortcomings. ObjectiveInstructor Xiiao han Ye on the basis of previous and combined with his own clinical experience, make blood circulation, expectorant collaterals, Endometriosis Treatment fat cholesterol to cured hyperlipidemia, and create his own capsule, Xinmaikang Capsule, obtained in animal experiments verification. By observing the clinical study of Xinmaikang Capsule hyperlipidemia treatment, evaluating the intervention of triglycerides (TC), total cholesterol (TG), low density lipoprotein (LDL-C), high density lipoprotein (HDL-C) and AI, while observing the clinical safety, and exploring the mechanism of its effect, to provide a basis for future clinical practice widely used.MethodsIn strict accordance with the inclusion criteria, selected 60 Cardiology patient cases who suffering from combined hyperlipidemia and was treated at Dongguan City Hospital inpatient and outpatient from April 2013 to June 2014 for the study, With randomized, single-blind, positive drug control methods, and according to Doll’s clinical cases of random table, divided the 60 cases into control group and test group randomly, each group 30 patients. On the basis of control of blood pressure, blood sugar, etc., two groups use medicine in accordance with the clinical routine. Test group used XinMaikang capsule,1 piece daily (Provide by Dongguan City Hospital Pharmacies); Control group was given Xinmaikang capsule (Provided by Beijing WBL Peking University Biotech Co., Ltd.,,0.3g/piece), twice a day, every times two ps, Were administered three months. During the observation period, all the lipid drugs, antioxidants and other drugs, as well as health and systolic efficacy medicine or similar medicine was prohibit used for the two groups. Observe the relevant safety indicators during treatment. Research, statistical and analysis the findings, then concluded.Results1. Efficacy Evaluation:Comparison of lipid changes:The test group Comparison with pre-treatment, lipid triglycerides (TC), total cholesterol (TG), low density lipoprotein (LDL-C) and AI levels were significantly lower, (p<0.05); but there was no significant change in HDL-L levels (P> 0.05), the effect of Xinmaikang capsule lower triglycerides (TC), total cholesterol (TG), AI rates were 80.0%,90.0% and 86.7%, increased high-density lipoprotein (HDL-C) 3.3%, the test group showed no significant difference efficacy with the control group (p> 0.05).2. The safety evaluation:During the clinical trials of the treatment group and the control group, no adverse reactions. There were no treatment-related abnormalities of blood, urine, feces, ECG, liver and kidney function before and after treatmentConclusionXinmaikang capsules has a significant effect in reducing TC, TG, LDL-C and AI, the same efficacy as Xuezhikang capsules. During clinical trials, no significant adverse reactions occurred, no side effects found during security checks. |
PDF Full Text Request